With new public investments and regenerative medicine grants, Canada’s health and biotech sector certainly didn’t take a summer break. In case you did, here’s a roundup of the health and biotechnology insights that defined August.
Trends Shaping Canada’s Health and Biotechnology Sector
Eldercare Is Doubling, and Our Healthcare System’s Not Ready
Eldercare demand in Canada is set to double over the next decade, with costs projected to reach $58.5 billion by 2031. That’s some serious pressure. And a few Ontario long-term care homes have already started trialing (and implementing) aging-in-place technology to meet the demand.
Bruyère Health adopted Esprit-ai’s fall and pressure injury prevention solution after a nine-month pilot. With under-mattress sensors and AI-powered alerts, the Esprit-ai Sense™ system tracks bed exits and repositioning in real-time. So far, that’s meant zero falls and strong adherence to care alerts across its long-term care facilities.
Perley Health is also trialing Esprit-ai in a year-long pilot. Pressure mats and room sensors are being used to flag movement, pressure shifts, and wandering risk. Their goal? To cut down on falls and risky behaviours while collecting real-time feedback from staff.
When pilots turn into practice this quickly, it’s clear: healthcare teams are ready for tools that solve real problems, and they’re moving fast to adopt them.
Genomics and Predictive Health Are Gaining Ground
Earlier this year, genomics got a major boost with the launch of the Canadian Precision Health Initiative (CPHI), an $81M in federal investment to build a national dataset of 100,000+ genomes. This summer, that momentum showed up in a series of new projects:
- Supercharging medical research: A new proteomics platform will make protein analysis faster and more affordable, speeding up drug discovery and disease research.
- Smarter cancer diagnostics: Two new prostate cancer tests are being developed to reduce unnecessary biopsies, improve outcomes, and lower health-care costs.
- Precision heart health: Researchers are using genomics-informed bio-inks to 3D-print heart tissue, creating safer models for disease study and drug testing.
Genome Canada also stepped into the spotlight with an RFP for a national economic study on the “biorevolution.” While the call has since closed, the message is clear: focus is moving from potential to proof. So if your team can make the connection from science to real markets, like faster drug pipelines, stronger food systems, or new industrial applications—funding and partnerships are ripe for the taking.
Health and Biotech Funding: Summer 2025 Updates
Whether you’re raising a round, scaling lab space, or still testing the waters, here’s what’s shaping the funding landscape right now.
- Stem Cell Network’s Incubation Investment Award Program: Announced August 6, this new program offers $250K to $1M for pre-seed and seed-stage regenerative medicine startups. Applications open September 8, so if you’re working on cell therapies, tissue engineering, or stem cell innovations, this could be the boost to help you move from concept to clinic.
- Health Commercialization Access Program (HCAP): Launched mid-July with $5M from FedDev Ontario, HCAP is designed for early-stage health startups to validate their tech inside Canadian healthcare systems. The program brings together non-dilutive funding, hands-on mentoring, and connections to more than 80 healthcare partners—giving founders a clearer path to test, refine, and grow.
- Ontario Life Sciences Innovation Fund: On June 10, Ontario committed $6.5M to 13 health-tech firms, each receiving $500K to scale R&D, validate in clinical settings, and prep for commercialization.
Canadian International Innovation Program (CIIP): From December 2–5, 2025, CIIP will lead a Canadian medical-tech delegation to Taiwan, with a focus on AI, diagnostics, AgeTech, wearables, and telehealth. The program covers up to 50% of costs like flights, hotels, and registration, giving startups a lower-risk way to step into Taiwan’s market and connect with potential partners. Applications close September 9, 2025.
Big Funding, Bigger Gaps: Why Biotech Wants More From Ottawa
Ottawa’s 2025 Federal Budget Submission doubled down on long-term backing for the Strategic Innovation Fund (SIF), Venture Capital Catalyst Initiative (VCCI), and the Health and Biosciences Economic Strategy Table (HERC). Together, these programs represent tens of billions in support for biotech founders.
But industry leaders say it’s not enough. On August 6, BIOTECanada urged the federal government to strengthen IP protections, update SR&ED tax credits (for early-stage biotech), and expand VC incentives.
So why push for more when billions are already on the table? Because funding alone doesn’t fix the structural gaps and without action Canada risks falling behind. Across the OECD, governments are pouring more into R&D, cutting red tape, and competing aggressively for talent and investment. The UK and Europe have even launched new life sciences strategies with tax breaks and funding designed to outpace rivals. Without that same level of ambition, Canada risks watching its best ideas (and talent) head elsewhere.
Inside Brampton’s Rise as a Health and Biotech Hotspot
With more than 1,300 companies and 22,000 people working in the sector, Brampton is tied to one of the largest biotech hubs in North America. Major players like Sun Pharma Canada, Medtronic, and Boston Scientific’s Brampton facility have anchored the industry here. But the city is proving just as fertile for early-stage innovation.
Lab space is easier to get, hiring doesn’t drag on, and local partners are stepping up to back practical health solutions. And it’s starting to show. This summer, Vessl Prosthetics, part of the Brampton Venture Zone, received $500,000 in funding from Ontario’s Life Sciences Innovation Fund. It’s a small but telling sign of how
What These Health and Biotech Insights Mean for Startups
From aging-in-place technology to genomics, the opportunities in health and biotech are wide open. This summer’s announcements made one thing crystal clear: startups that can align with market needs will be best positioned to benefit.
BHive works with health and biotech teams that are ready to turn research into real-world impact. If Ontario is part of your growth strategy, now’s the time to connect with an ecosystem that can help refine your approach, open doors to partners, and prepare you for the funding opportunities ahead. See how BHive can help.